Like what was observedin the context of CRC, METTL3 was foundto target SOX2 and consequently support the maintenance of highlytumorigenic glioma stem-like cells (GSCs) and the de-differentiationof glioma cells. The gene discussed is SOX2; the disease is central nervous system cancer.